Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 94
Filtrar
1.
Vaccine ; 42(9): 2115-2116, 2024 Apr 02.
Artículo en Inglés | MEDLINE | ID: mdl-38360472
2.
Vaccine ; 40(22): 2999-3008, 2022 05 11.
Artículo en Inglés | MEDLINE | ID: mdl-35459556

RESUMEN

BACKGROUND: There is an urgent need for improved influenza vaccines especially for older adults due to the presence of immunosenescence. It is therefore highly relevant to compare enhanced influenza vaccines with traditional influenza vaccines with respect to their effectiveness. OBJECTIVE: To compare vaccine efficacy and effectiveness of adjuvanted influenza vaccines (aTIV/aQIV) vs. non-adjuvanted standard-dose (TIV/QIV) and high-dose (TIV-HD/QIV-HD) influenza vaccines regarding influenza-related outcomes in older adults, complementing findings from the European Centre for Disease Prevention and Control (ECDC)'s systematic review of enhanced seasonal influenza vaccines from February 2020. METHODS: A systematic literature search was conducted in Embase and MEDLINE to identify randomised controlled trials, observational studies and systematic reviews, published since ECDC's systematic review (between 7 February 2020 and 6 September 2021). Included studies were appraised with either the Cochrane Risk of Bias tool, ROBINS-I or AMSTAR 2. RESULTS: Eleven analyses from nine real-world evidence (RWE) studies comprising ∼53 million participants and assessing the relative vaccine effectiveness (rVE) of aTIV vs. TIV, QIV and/or TIV-HD in adults aged ≥65 years over the 2006/07-2008/09 and 2011/12-2019/20 influenza seasons were identified. Nine analyses found that aTIV was significantly more effective than TIV and QIV in reducing influenza-related outcomes by clinical setting and suspected influenza outbreaks (rVE ranging from 7.5% to 25.6% for aTIV vs. TIV and 7.1% to 36.3% for aTIV vs. QIV). Seven analyses found similar effectiveness of aTIV vs. TIV-HD in reducing influenza-related medical encounters, inpatient stays and hospitalisations/emergency room visits. In three analyses, aTIV was significantly more effective than TIV-HD in reducing influenza-related medical encounters and office visits (rVE ranging from 6.6% to 16.6%). Risk of bias of identified studies was moderate to high. CONCLUSIONS: Our study suggests that both adjuvanted and high-dose vaccines are effective alternatives for vaccination programmes in older adults and preferable over conventional standard-dose vaccines.


Asunto(s)
Vacunas contra la Influenza , Gripe Humana , Adyuvantes Inmunológicos , Anciano , Humanos , Gripe Humana/prevención & control , Polisorbatos , Escualeno
3.
MMW Fortschr Med ; 155 Suppl 1: 25-31, 2013 Mar 21.
Artículo en Alemán | MEDLINE | ID: mdl-23678668

RESUMEN

BACKGROUND: Chronic pain in the elderly is common. Especially in the elderly inadequate treatment of pain can cause significant functional impairmentand deterioration of qualityof life. METHODS: Theaim of this post-marketing surveillance study was to collect data from clinical practice on the analgesic efficacy and safety of the 7-day transdermal buprenorphine patch in patients with chronic non-malignant pain pre-treated with opioids. A total of 2713 elderly multimorbid patients were switched to 7-day transdermal buprenorphine patch from previous opioid treatment mainly due to inadequate analgesia. 83% of patients received a 7-day transdermal buprenorphine patch dosage > or = 10 microg/h. During the 8-weekobservation period, data on pain intensity, quality of sleep/life (NRS-11 point scales) and safety wererecorded. RESULTS: Mean pain intensity decreased by 4 points with 7-day transdermal buprenorphine patch (p < or = 0.001). Quality of sleep and life as well as social activities and self-reliance improved significantly. Compliance and tolerability were assessed as very good/good in > 90% of patients. Adverse drug reactions (ADRs) occurred in 3% of patients and corresponded to 90.1% to the already-known spectrum of ADRs of 7-daytransdermal buprenorphinepatch. CONCLUSIONS: The results confirm that elderly patients with opioid pre-treatment benefit from a switch to 7-day transdermal buprenorphine patch with regard to reduction of pain and improved quality of life.


Asunto(s)
Analgésicos Opioides/administración & dosificación , Buprenorfina/administración & dosificación , Dolor Crónico/tratamiento farmacológico , Administración Cutánea , Anciano , Anciano de 80 o más Años , Analgésicos Opioides/efectos adversos , Buprenorfina/efectos adversos , Dolor Crónico/psicología , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Sustitución de Medicamentos , Quimioterapia Combinada , Estudios de Seguimiento , Alemania , Humanos , Dimensión del Dolor/efectos de los fármacos , Satisfacción del Paciente , Estudios Prospectivos , Calidad de Vida/psicología
4.
Prostaglandins Leukot Essent Fatty Acids ; 87(6): 197-203, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23142364

RESUMEN

BACKGROUND: Conjugated linoleic acids (CLAs) are natural dairy food components that exhibit a unique body of potential health benefits in animals and man, including anti-cardiovascular disease and anti-cancer effects. Several studies have demonstrated that fatty acid synthase (FAS) levels (protein and mRNA) are over expressed in many carcinomas. Sterol regulatory element binding proteins (SREBPs) are transcription factors that regulate genes involved in lipid metabolism, including FAS. METHODS: Breast cancer cell lines, MCF-7 and MDA-MB-231 were treated with CLAs to investigate the regulation of SREBP-1c and FAS expression. RESULTS: In MDA-MB-231 cells, SREBP-1c and FAS were co-ordinately decreased by treatment with 25 µM CLA 9-11 and 10-12. In MCF-7 cells, the decrease in SREBP-1c and FAS expression was dependant on the concentration of CLA used. CONCLUSIONS: The data suggest a differential effect of CLAs on SREBP-1c and FAS in estrogen receptor-positive (MCF-7) compared to estrogen receptor-negative (MDA-MB-231) breast cancer cells.


Asunto(s)
Apoptosis , Neoplasias de la Mama/enzimología , Acido Graso Sintasa Tipo I/metabolismo , Regulación Neoplásica de la Expresión Génica , Ácidos Linoleicos Conjugados/metabolismo , Proteínas de Neoplasias/metabolismo , Receptores de Estrógenos/metabolismo , Antineoplásicos/metabolismo , Neoplasias de la Mama/metabolismo , Línea Celular Tumoral , Acido Graso Sintasa Tipo I/genética , Femenino , Humanos , Proteínas de Neoplasias/genética , Concentración Osmolar , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , ARN Mensajero/metabolismo , Proteínas de Unión a los Elementos Reguladores de Esteroles/genética , Proteínas de Unión a los Elementos Reguladores de Esteroles/metabolismo
5.
Artículo en Inglés | MEDLINE | ID: mdl-21995886

RESUMEN

Omega-3 (n-3) fatty acids inhibit breast and prostate cancer cell growth. We previously showed that N-acylethanolamine derivatives of n-3 (n-3-NAE) are endocannabinoids, which regulate cancer cell proliferation. These n-3-NAE are synthesised in certain cells/tissues, after supplementing with fatty acids, however, no one has assessed whether and to what extent this occurs in cancer cells. We determined levels of endogenous n-3-NAEs in hormone sensitive and insensitive prostate and breast cancer cells and subsequent effects on other endocannabinoids (anandamide and 2-arachidonoylglycerol), before and after supplementing with DHA and EPA fatty acids, using HPLC tandem mass spectrometry. This is the first study reporting that n-3-NAEs are synthesised from their parent n-3 fatty acids in cancer cells, regardless of tumour type, hormone status or the presence of fatty acid amide hydrolase. This could have important implications for the use of n-3 fatty acids as therapeutic agents in breast and prostate cancers expressing cannabinoid receptors.


Asunto(s)
Neoplasias de la Mama/metabolismo , Moduladores de Receptores de Cannabinoides/biosíntesis , Etanolaminas/metabolismo , Ácidos Grasos Omega-3/metabolismo , Neoplasias de la Próstata/metabolismo , Amidohidrolasas/antagonistas & inhibidores , Amidohidrolasas/metabolismo , Moduladores de Receptores de Cannabinoides/química , Línea Celular Tumoral , Femenino , Humanos , Masculino , Espectrometría de Masas en Tándem
6.
Probiotics Antimicrob Proteins ; 3(3-4): 168-74, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26781677

RESUMEN

It has been demonstrated that probiotic supplementation has positive effects in several murine models of disease through influences on host immune responses. This study examined the effect of Lactobacillus casei strain Shirota (L. casei Shirota) on the blood glucose, C-reactive protein (CRP), Interleukin-6 (IL-6), Interleukin-4 (IL-4), and body weight among STZ-induced diabetic rats. Diabetes mellitus was induced by streptozotocin (STZ, 50 mg/kg BW) in male Sprague-Dawley rats. Streptozotocin caused a significant increase in the blood glucose levels, CRP, and IL-6. L. casei Shirota supplementation lowered the CRP and IL-6 levels but had no significant effect on the blood glucose levels, body weight, or IL-4. Inflammation was determined histologically. The presence of the innate immune cells was not detectable in the liver of L. casei Shirota-treated hyperglycemic rats. The probiotic L. casei Shirota significantly lowered blood levels of pro-inflammatory cytokines (IL-6, CRP) and neutrophils in diabetic rats, showing a lower risk of diabetes mellitus and its complications.

7.
Cancer Biomark ; 7(1): 39-46, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-21045263

RESUMEN

Breast cancer aetiology is unclear despite comprising approximately 28% of female cancers. Several risk factors are known. Not all women exhibiting established risk factors will develop breast cancer but many without recognised risk factors will, indicating involvement of unknown risk factors. Impaired basal or oxidation-stimulated gene expression of redox enzymes, particularly Glutathione Peroxidase 1 and 4 (GPX1 and 4), resulting in increased oxidative stress, could be an "unknown" risk factor in breast cancer. We determined whether basal expression of GPX1 and 4, two major redox enzymes, in Peripheral Blood Mononuclear Cells (PBMNC) and/or their stimulated expression (oxidative stress) was impaired in women with breast cancer who have no known markers of risk compared with control women without breast cancer. A significant 30% impairment (p< 0.01) in basal PBMNC GPX4, but not GPX1, gene expression was observed in cancer patients. Oxidative stress stimulation in vitro did not increase GPX4 expression significantly in cancer patients or control women whereas GPX1 expression was significantly increased (30%, p<0.05) only in the cancer group. Attenuation of GPX4 mRNA expression in PBMNC suggests this could be a simple,early biomarker for future breast cancer risk in the high proportion of women without known risk factors who eventually contract the disease.


Asunto(s)
Neoplasias de la Mama/genética , Glutatión Peroxidasa/biosíntesis , Leucocitos Mononucleares/enzimología , Adulto , Biomarcadores de Tumor/biosíntesis , Femenino , Expresión Génica , Glutatión Peroxidasa/sangre , Humanos , Peróxido de Hidrógeno/farmacología , Fosfolípido Hidroperóxido Glutatión Peroxidasa , ARN Mensajero/metabolismo , Factores de Riesgo , Glutatión Peroxidasa GPX1
9.
Dtsch Med Wochenschr ; 134 Suppl 2: S65-70, 2009 Apr.
Artículo en Alemán | MEDLINE | ID: mdl-19353474

RESUMEN

Vaccinations are one of the most effective measures of preventing infection illnesses. In Germany adequate vaccination rates have so far been achieved only partially. 85 - 90 % of all vaccinations are carried out by the general practitioner, who in this context plays a key role. He/she assumes varied duties such as advice on vaccinations, administering vaccines and recording it. Visits to a doctor should also be used for checking on vaccination protection and if necessary its updating. In addition continual updating the vaccination recommendations of the Permanent Vaccination Commission (Ständige Impfkommission) should be followed as guideline. Regardless of the recommended vaccinations for adults additional indications for vaccinating individuals e. g. pertussis vaccination, can be put into effect. Vaccinations of adults should always be carried out by taking into account a persons?s life situation.


Asunto(s)
Control de Enfermedades Transmisibles/normas , Médicos de Familia , Responsabilidad Social , Vacunación/normas , Adulto , Humanos , Vacuna contra la Tos Ferina/normas , Vacuna contra la Tos Ferina/uso terapéutico
10.
Eur J Clin Nutr ; 63(6): 778-86, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18772894

RESUMEN

BACKGROUND/OBJECTIVES: Dietary addition of either conjugated linoleic acid (CLA) or n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) has been shown to alter adiposity and circulating lipids, risk markers of cardiovascular diseases. However, CLA may decrease insulin sensitivity, an effect that may be reversed by n-3 LC-PUFA. Thus, the potential of CLA plus n-3 LC-PUFA to affect insulin secretion and sensitivity in non-diabetic young and old, lean and obese subjects was tested. SUBJECTS/METHODS: CLA (3 g daily) plus n-3 LC-PUFA (3 g daily) or control oil (6 g daily) was given to lean (n=12; BMI 20-26 kg/m(2)) or obese (n=10; BMI 29-35 kg/m(2)) young (20-37 years old) or lean (n=16) or obese (n=11) older men (50-65 years) for 12 weeks. The study had a double-blind, placebo-controlled randomized crossover design, and primary end points were insulin secretion and sensitivity during a standardized meal test, evaluated by modeling glucose, insulin and C-peptide data. RESULTS: The combination was well tolerated. There was no significant difference in fasting levels of glucose, insulin or C-peptide after CLA/n-3 LC-PUFA treatment compared with control oil. Neither insulin secretion nor estimated sensitivity was affected by CLA/n-3 LC-PUFA in lean or obese young subjects or in older lean subjects. However, in older obese subjects, estimated insulin sensitivity was reduced with CLA/n-3 LC-PUFA compared with control (P=0.024). CONCLUSIONS: The results do not support beneficial effects of CLA/n-3 LC-PUFA for beta-cell dysfunction or insulin resistance in humans but suggest that insulin sensitivity in older obese subjects is reduced.


Asunto(s)
Ácidos Grasos Omega-3/farmacología , Resistencia a la Insulina , Insulina/metabolismo , Ácidos Linoleicos Conjugados/farmacología , Obesidad/tratamiento farmacológico , Adulto , Factores de Edad , Anciano , Glucemia , Proteína C-Reactiva/metabolismo , Estudios Cruzados , Método Doble Ciego , Ácidos Grasos Omega-3/uso terapéutico , Humanos , Secreción de Insulina , Ácidos Linoleicos Conjugados/uso terapéutico , Masculino , Persona de Mediana Edad , Adulto Joven
11.
Artículo en Inglés | MEDLINE | ID: mdl-18036803

RESUMEN

We previously showed conjugated linoleic acids (CLA) inhibited TNF-alpha-induced monocyte (THP-1) adhesion to human umbilical vein endothelial cells (HUVEC) in vitro which involved an increase in platelet activating factor (PAF). Here we show adhesion molecule (ADM) regulation by fatty acids and the differing role of nuclear factor kappa B (NF-kappaB) activation in HUVEC and vascular smooth muscle cells (vSMC). CLA and omega-3 long-chain polyunsaturated fatty acids (PUFA) (FA) reduced TNF-alpha-induced expression of ADMs (intercellular adhesion molecule-1 (ICAM-1); vascular cell adhesion molecule-1 (VCAM-1) but not E-selectin) on HUVEC and vSMC to different extents depending on FA type and concentration, cell type and method of analysis. IkappaBalpha phosphorylation in HUVEC and vSMC and transient transfection with NF-kappaB-luciferase reporter plasmid (HUVEC only) indicated differential NF-kappaB involvement during FA modulation (cis-9, trans-11; trans-10, cis-12 and a 50:50 mix of both CLA isomers; eicosapentaenoic acid (EPA); docosahexaenoic acid (DHA)). TNF-alpha-induced ADM expression in both cell types by 2-10-fold. In HUVEC, CLA t10, c12 and CLA mix (50:50 mixture of CLA c9, t11 and t10, c12) and EPA and DHA reduced ICAM-1 expression (15-35%) at 12.5, 25 and/or 50 microM. VCAM-1 expression was reduced by 25 microM t10, c12 isomer and mix; omega-3 PUFA and other concentrations of CLA and TNF-alpha-induced E-selectin expression were unaffected. TNFalpha-induced inhibitor kappa B (IkappaB) phosphorylation was biphasic peaking at 5 min in both cell types and 60 and 120 min in HUVEC and SMC, respectively. IkappaBalpha phosphorylation and NF-kappaB activity was reduced (29% and 30%, respectively) by 25 microM CLA mix. n-3 PUFA did not reduce IkappaBalpha phosphorylation or NF-kappaB activity but reduced ADM expression. We show that n-3 PUFA and CLA reduce expression of ADM on HUVEC and vSMC. This reflected reduced adherence of monocytes to HUVEC previously reported by our group. Reduction of ICAM-1 and VCAM-1 protein expression by n-3 PUFA was less dependent on the NF-kappaB pathway than reduction by CLA which reflected the parallel attenuation of NF-kappaB activity. This indicated involvement of other transcription factors (i.e. AP-1) in the FA regulation of ADM expression and has, to our knowledge, not been previously reported.


Asunto(s)
Células Endoteliales/metabolismo , Ácidos Grasos Omega-3/farmacología , Molécula 1 de Adhesión Intercelular/metabolismo , Ácidos Linoleicos Conjugados/farmacología , Miocitos del Músculo Liso/metabolismo , FN-kappa B/metabolismo , Molécula 1 de Adhesión Celular Vascular/metabolismo , Línea Celular , Células Cultivadas , Endotelio Vascular/citología , Endotelio Vascular/metabolismo , Humanos , Músculo Liso Vascular/citología , Músculo Liso Vascular/metabolismo , Fosforilación , Factor de Necrosis Tumoral alfa/metabolismo , Venas Umbilicales
13.
Artículo en Inglés | MEDLINE | ID: mdl-17197163

RESUMEN

Increasing evidence indicates that oxidative injury exists in schizophrenia. Although it may not be the main cause, oxidative damage has been suggested to contribute to the pathophysiology and may account for deteriorating course and poor outcome in schizophrenia. A human study was undertaken, therefore, to investigate possible differences in biomarkers of DNA, lipid and protein oxidation in schizophrenic (n=16) and control subjects (n=17). Plasma vitamin C levels were also compared in both groups. Cellular DNA damage and plasma protein carbonyl levels were increased in the schizophrenic group compared to control subjects but not significantly. However, DNA damage in lymphocytes from the male schizophrenic group was significantly higher than the female group. Biomarkers of lipid peroxidation and plasma vitamin C levels also revealed no significant difference between the two groups under investigation, although a significant elevation in plasma vitamin C was observed in the female control group when compared to the male groups.


Asunto(s)
Biomarcadores/metabolismo , Trastornos Psicóticos/metabolismo , Adulto , Antipsicóticos/uso terapéutico , Ácido Ascórbico/sangre , Biomarcadores/análisis , Estudios de Casos y Controles , Células Cultivadas , Criopreservación , Daño del ADN , Femenino , Humanos , Peróxido de Hidrógeno/farmacología , Peroxidación de Lípido/efectos de los fármacos , Linfocitos/efectos de los fármacos , Linfocitos/metabolismo , Masculino , Persona de Mediana Edad , Estrés Oxidativo , Carbonilación Proteica , Trastornos Psicóticos/tratamiento farmacológico
14.
Surgeon ; 3(3): 139-44, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16075997

RESUMEN

The understanding of the role of nutrition in the surgical patient has lead to major developments in the nutritional support of patients undergoing surgery. Reductions in morbidity by ensuring that patients receive optimal nutritional support can be achieved. Furthermore, the use of nutrients to modify immune, inflammatory and metabolic processes also offers new possibilities for reducing morbidity following major surgery. However, we are only at an embryonic stage in our understanding of how nutrients and nutrition affect the genome and this knowledge offers exciting possibilities in the future for modulating many key intracellular processes, particularly in the patient with cancer.


Asunto(s)
Fenómenos Fisiológicos de la Nutrición , Atención Perioperativa , Procedimientos Quirúrgicos Operativos , Humanos , Inmunidad , Control de Infecciones , Apoyo Nutricional , Complicaciones Posoperatorias/prevención & control , Investigación
15.
Eur J Clin Nutr ; 59(4): 508-17, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15674307

RESUMEN

OBJECTIVES: This study investigated the effect of dietary CLA supplementation (3g/day; 50:50 mix of the two major isomers) on the immune system and plasma lipids and glucose of healthy human (male and female) volunteers. DESIGN: Double-blind, randomized, reference-controlled study. SUBJECT AND INTERVENTION: A total of 28 healthy male and female participants aged 25-50 y received either high oleic sunflower oil (reference) or 50% CLA 9-11 and 50% CLA 10-12 CLA isomers (50:50 CLA-triglyceride form). The treatments were given as supplements in soft-gel capsules providing a total 3 g (6 x 500 mg capsules) per day in treatment groups for 12 weeks. A 12-week washout period followed the intervention period. RESULTS: Levels of plasma IgA and IgM were increased (P < 0.05 and 0.01 respectively), while plasma IgE levels were decreased (P < 0.05). CLA supplementation also decreased the levels of the proinflammatory cytokines, TNF-alpha and IL-1beta (P < 0.05), but increased the levels of the anti-inflammatory cytokine, IL-10 (P < 0.05). Another aspect of immune function, delayed type hypersensitivity (DTH) response, was decreased during and after CLA supplementation (P < 0.05). However, plasma glucose, lipids, lymphocyte phenotypic results were not affected significantly by CLA. CONCLUSION: This is the first study to show that CLA, a fatty acid naturally found in dairy and meat products, can beneficially affect immune function in healthy human volunteers. SPONSORSHIP: This study was supported by Loders-Croklaan, The Netherlands and SEERAD (Scottish Executive Environmental Rural and Agriculture Department).


Asunto(s)
Suplementos Dietéticos , Inmunidad/efectos de los fármacos , Ácidos Linoleicos Conjugados/farmacología , Adulto , Glucemia/efectos de los fármacos , Proteína C-Reactiva/efectos de los fármacos , Citocinas/biosíntesis , Método Doble Ciego , Femenino , Humanos , Hipersensibilidad Tardía , Inmunidad/fisiología , Inmunoglobulinas/sangre , Inmunoglobulinas/efectos de los fármacos , Lípidos/sangre , Linfocitos/efectos de los fármacos , Masculino , Valores de Referencia , Factores Sexuales , Factores de Tiempo
16.
Nutr Hosp ; 19(6): 325-32, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15672647

RESUMEN

The clinical trials of immunonutrition that we have undertaken have often been small, single centre studies. They have often been of limited statistical power and have often included patients with a variety of underlying disease states and at different points in the disease process. Three meta-analysis and a consensus statement in conjunction with a systematic review, have been performed in an attempt to overcome many of these limitations and understand further the clinical place for immunonutrition. However, there are still many questions regarding the place of immunonutrition in clinical practice that we still do not understand or have definitive answers to. For example, do we really know what is the optimal combination of nutrients and in what quantities they should be provided? Do we understand any potential interactions that might occur between these nutrients? What is the effect of the patients nutritional state? When and for how long should immunonutrition provided? What is the impact of the patients' underlying disease process and how does this interact with the provision of immunonutrition? At the present time whilst there is some indication and evidence as to which patients might benefit most, and as to those who may not benefit or even suffer detrimental effects from immunonutrition, we still can not answer these questions with any definitive authority. It is essential now that we undertake large well designed, well controlled multicentre studies with adequate statistical power to answer these questions. The indications are that immunonutrition has the potential to help patients but its place must be more clearly defined before its widespread acceptance into clinical practice is based on sound scientific evidence.


Asunto(s)
Inmunidad/fisiología , Fenómenos Fisiológicos de la Nutrición/fisiología , Ensayos Clínicos como Asunto , Medicina Basada en la Evidencia , Humanos
17.
Biofactors ; 18(1-4): 265-70, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-14695942

RESUMEN

The aim of this study was to investigate the role of coenzyme Q on the mRNA abundance of PHGPx and the reactive oxygen species (ROS) production in two different cell lines from human prostate, a line of non cancer cells (PNT2) and a line of cancer cells (PC3). Results showed that malignant cells markedly differ in their response to coenzyme Q compared to non-malignant cells, with no changes in PHGPx expression and greater ROS production. Furthermore coenzyme Q supplementation significantly lowered cell growth of the PC3 cancer line without affecting the PNT2. If these results are confirmed with additional experiments, it could represent a novel and interesting approach on the biomedical use of coenzyme Q10 in cancer therapy.


Asunto(s)
Radicales Libres/metabolismo , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Glutatión Peroxidasa/genética , Próstata/enzimología , Neoplasias de la Próstata/enzimología , Ubiquinona/farmacología , Línea Celular , Humanos , Masculino , Mitocondrias/metabolismo , Próstata/efectos de los fármacos , Próstata/ultraestructura , Neoplasias de la Próstata/patología , ARN Mensajero/análisis , Células Tumorales Cultivadas
18.
Artículo en Inglés | MEDLINE | ID: mdl-12324239

RESUMEN

Fats have been adversely implicated in the aetiology of many forms of cancer yet evidence is accumulating that certain types of fatty acids have anticancer properties. This is well documented for fish-oil fatty acids of the n-3 family. Recently, fatty acids found to occur naturally in ruminant-derived food products were found to have anticancer properties. These fatty acids were identified as conjugated linoleic acids (CLAs) derived from the parent linoleic acid by its partial hydrogenation by rumen bacteria. Studies with tumour-bearing animals have shown that consumption of CLAs particularly with regard to breast and prostate cancer is beneficial. Studies with cancer cells have also shown that these fatty acids can inhibit cell proliferation and induce cell death. However, little is known regarding the mechanisms of action of these CLAs. In particular, which cellular signal mechanisms are regulated by CLAs which can explain their anticancer properties. We have shown that CLAs specifically up-regulate cell signal systems at the level of gene expression (mRNA, protein) in human breast and prostate cancer cells which are responsible for the induction of apoptosis or programmed cell death. These findings support the anticancer effects of CLA found in animal models and indicate similar effects could occur in man.


Asunto(s)
Antineoplásicos/farmacología , Ácidos Linoleicos/farmacología , Neoplasias/dietoterapia , Transducción de Señal/efectos de los fármacos , Animales , Antineoplásicos/administración & dosificación , Grasas de la Dieta/administración & dosificación , Grasas de la Dieta/farmacología , Humanos , Ácidos Linoleicos/administración & dosificación , Neoplasias/etiología , Neoplasias/prevención & control
19.
Biochem Biophys Res Commun ; 283(4): 806-12, 2001 May 18.
Artículo en Inglés | MEDLINE | ID: mdl-11350056

RESUMEN

Polyunsaturated fatty acids influence the aetiology of prostate cancer. Their effects on cellular mechanisms regulating prostate tumorigenesis are unclear. Using prostate cancer cells (LNCaP), we determined effects of n-9-OA, n-6-LA, and n-3-EPA on total PKC and its isoforms in relation to cell proliferation and PSA production. PKC-alpha, delta, gamma, iota, mu, and zeta were present in LNCaP cells; PKC-beta, epsilon, eta, and theta isoforms were not. PKC-alpha was detected only in cytosol; PKC-delta, iota, gamma, and mu were present in cytosol and in membranes. Fatty acids increased cell proliferation, total PKC activity and elicited pro-proliferative effects on specific PKC isoforms (PKC-delta and -iota). EPA and LA increased total PKC activity and reduced membrane-abundance of PKC-delta. OA reduced cytosolic and membrane PKC-delta. Only EPA reduced PKC-gamma membrane abundance. Fatty acids enhanced cytosolic PKC-iota abundance but only EPA and to a lesser extent LA increased its membrane content. Changes in PKC-delta, -iota, and -gamma did not affect PSA production.


Asunto(s)
División Celular/efectos de los fármacos , Ácidos Grasos Insaturados/farmacología , Isoenzimas/metabolismo , Neoplasias de la Próstata/enzimología , Proteína Quinasa C/metabolismo , Humanos , Masculino , Antígeno Prostático Específico/biosíntesis , Neoplasias de la Próstata/inmunología , Neoplasias de la Próstata/patología , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA